Follow The Filings

GRDN Guardian Pharmacy Services

Guardian Pharmacy Services earnings company data as of 4:48 AM ET 10/23

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 9 Nov EPS 0.29 — —
Rev — — —

Insider trades

Open-market buys and sales by GRDN's executives, directors and 10% owners in the last 12 months, from their Form 4s

All GRDN insider trades
  • $100K bought by 1 insider
  • $419M sold by 9 insiders outside a trading plan
  • None no planned (10b5-1) sales
  1. David K Morris See Remarks
    Sale
    $5.6M 187,855 shares at $29.68 43% of stake
    Traded Mar 20 Filed Mar 24
  2. Pharmacy Investors, LLC Insider
    Sale
    $24.6M 827,636 shares at $29.68 44% of stake
    Traded Mar 20 Filed Mar 24
  3. Fred Burke See Remarks
    Sale
    $19.9M 671,432 shares at $29.68 44% of stake
    Traded Mar 20 Filed Mar 24
  4. Thomas J Salentine Jr. Director
    Sale
    $106M 3,570,677 shares at $29.68 44% of stake
    Traded Mar 20 Filed Mar 24
  5. John Ackerman Director
    Sale
    $32.8M 1,103,364 shares at $29.68 76% of stake
    Traded Mar 20 Filed Mar 24
  6. Kendall Forbes See Remarks
    Sale
    $10.3M 346,672 shares at $29.68 43% of stake
    Traded Mar 20 Filed Mar 24
  7. Cardinal Equity Fund, L.P. Insider
    Sale
    $8.2M 275,728 shares at $29.68 44% of stake
    Traded Mar 20 Filed Mar 24
  8. Steven D Cosler Director
    Buy
    $100K 3,370 shares at $29.61 +16% to stake
    Traded Dec 3, 2025 Filed Dec 5, 2025

Also filed in the last 12 months, not counted as buying or selling: 27 option exercises, 5 stock grants, and 2 gifts.

SEC filings

Recent issuer filings from EDGAR, 12 shown.

Filed Form Detail Links
SCHEDULE 13D/A —
8-K 8.01
8-K 2.02,9.01
10-Q
8-K 5.02,7.01,9.01
8-K 1.01,2.03,9.01
8-K 5.07
SCHEDULE 13G —
8-K 2.02,9.01
10-Q
DEF 14A
DEFA14A

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.